HUE053347T2 - Glikopeptid-készítmények - Google Patents

Glikopeptid-készítmények

Info

Publication number
HUE053347T2
HUE053347T2 HUE19174849A HUE19174849A HUE053347T2 HU E053347 T2 HUE053347 T2 HU E053347T2 HU E19174849 A HUE19174849 A HU E19174849A HU E19174849 A HUE19174849 A HU E19174849A HU E053347 T2 HUE053347 T2 HU E053347T2
Authority
HU
Hungary
Prior art keywords
glycopeptide
preparations
glycopeptide preparations
Prior art date
Application number
HUE19174849A
Other languages
English (en)
Hungarian (hu)
Inventor
Ivona Jasprica
Sabina Keser
Katarina Pindric
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE053347(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of HUE053347T2 publication Critical patent/HUE053347T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HUE19174849A 2014-11-06 2015-11-06 Glikopeptid-készítmények HUE053347T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30

Publications (1)

Publication Number Publication Date
HUE053347T2 true HUE053347T2 (hu) 2021-06-28

Family

ID=54478023

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15791287A HUE049857T2 (hu) 2014-11-06 2015-11-06 Glikopeptid-készítmények
HUE19174849A HUE053347T2 (hu) 2014-11-06 2015-11-06 Glikopeptid-készítmények

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE15791287A HUE049857T2 (hu) 2014-11-06 2015-11-06 Glikopeptid-készítmények

Country Status (29)

Country Link
US (8) US10188697B2 (enExample)
EP (4) EP3542812B1 (enExample)
JP (2) JP6797795B2 (enExample)
KR (2) KR102763211B1 (enExample)
CN (1) CN107073072B (enExample)
AU (1) AU2015341763B2 (enExample)
BR (1) BR112017009405B1 (enExample)
CL (1) CL2017001139A1 (enExample)
CO (1) CO2017005391A2 (enExample)
CR (1) CR20170234A (enExample)
CY (2) CY1122960T1 (enExample)
DK (2) DK3542812T3 (enExample)
EA (1) EA035368B1 (enExample)
ES (2) ES2769849T3 (enExample)
HR (2) HRP20200101T1 (enExample)
HU (2) HUE049857T2 (enExample)
IL (1) IL252120B (enExample)
MX (1) MX387229B (enExample)
NZ (1) NZ731955A (enExample)
PH (1) PH12017500720A1 (enExample)
PL (2) PL3215173T3 (enExample)
PT (2) PT3542812T (enExample)
RS (2) RS59851B1 (enExample)
SA (1) SA517381446B1 (enExample)
SG (1) SG11201703568WA (enExample)
SI (2) SI3542812T1 (enExample)
TN (1) TN2017000182A1 (enExample)
WO (1) WO2016071495A1 (enExample)
ZA (1) ZA201702767B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6797795B2 (ja) * 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスXellia Pharmaceuticals ApS グリコペプチド組成物
ES3028295T3 (en) * 2015-12-24 2025-06-18 Univ Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
MX388732B (es) * 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
EP3544616A4 (en) * 2016-11-23 2020-12-09 Gufic Biosciences Limited LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
US20220184173A1 (en) 2019-03-08 2022-06-16 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
US11433115B2 (en) * 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
JPWO2023171588A1 (enExample) * 2022-03-08 2023-09-14
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
AU2023359652A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
WO2025006267A1 (en) * 2023-06-26 2025-01-02 Venn Biosciences Corporation Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis
GB202405997D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions
GB202405996D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
RU2145609C1 (ru) 1994-01-28 2000-02-20 Эли Лилли Энд Компани Производные гликопептида или их соли, способ получения, фармацевтическая композиция
WO1997019690A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
WO2003082273A1 (en) * 2002-03-26 2003-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
EP1578362A4 (en) 2002-07-09 2008-11-05 Point Therapeutics Inc COMBINATION THERAPY WITH A BOROPROLINE COMPOUND
CN1802090A (zh) * 2002-07-09 2006-07-12 尖端医疗有限公司 硼脯氨酸化合物组合治疗
KR20120056310A (ko) 2002-11-18 2012-06-01 비큐론 파마세티컬스 인코포레이티드 박테리아 감염 치료를 위한 달바반신 투여 방법
UA91208C2 (ru) 2005-02-14 2010-07-12 Венус Ремедиз Лимитед Фармацевтическая композиция, которая содержит антибактериальный гликопептид и цефалоспорин, для терапии резистентных инфекционных состояний
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发(河北)有限公司 促胰岛素肽缀合物制剂
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
CA2836643C (en) * 2011-05-19 2017-11-14 Savara, Inc. Dry powder vancomycin compositions and associated methods
WO2014026052A1 (en) 2012-08-08 2014-02-13 Vanderbilt University Composition with biofilm dispersal agents
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2014194296A1 (en) * 2013-05-30 2014-12-04 Scidose, Llc Formulations of vancomycin
CN106573037A (zh) 2014-03-14 2017-04-19 库蒂斯制药公司 用于万古霉素口服液的组合物和方法
JP6797795B2 (ja) * 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスXellia Pharmaceuticals ApS グリコペプチド組成物
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
EA201790997A1 (ru) 2017-09-29
CN107073072B (zh) 2021-06-18
KR20170078830A (ko) 2017-07-07
US20250288640A1 (en) 2025-09-18
US10188697B2 (en) 2019-01-29
AU2015341763B2 (en) 2019-01-17
CR20170234A (es) 2018-01-15
DK3542812T3 (da) 2021-04-12
US20230158101A1 (en) 2023-05-25
CL2017001139A1 (es) 2017-12-01
PT3542812T (pt) 2021-04-20
EP3542812B1 (en) 2021-01-13
CY1122960T1 (el) 2021-10-29
RS59851B1 (sr) 2020-02-28
US20180133286A1 (en) 2018-05-17
KR102763211B1 (ko) 2025-02-04
US10849956B2 (en) 2020-12-01
EA035368B1 (ru) 2020-06-03
PT3215173T (pt) 2020-04-03
SG11201703568WA (en) 2017-05-30
CY1124011T1 (el) 2022-05-27
US11000567B2 (en) 2021-05-11
BR112017009405A2 (pt) 2018-01-02
US11628200B2 (en) 2023-04-18
ZA201702767B (en) 2018-12-19
JP6797795B2 (ja) 2020-12-09
HRP20200101T1 (hr) 2020-04-03
JP7032488B2 (ja) 2022-03-08
SI3215173T1 (sl) 2020-03-31
SA517381446B1 (ar) 2020-09-21
EP3542812A1 (en) 2019-09-25
KR102603756B1 (ko) 2023-11-16
HRP20210342T8 (hr) 2022-01-21
US20170348385A1 (en) 2017-12-07
US12161690B2 (en) 2024-12-10
US20220354927A1 (en) 2022-11-10
WO2016071495A1 (en) 2016-05-12
SI3542812T1 (sl) 2021-04-30
NZ731955A (en) 2023-07-28
EP4147710A1 (en) 2023-03-15
ES2769849T3 (es) 2020-06-29
BR112017009405B1 (pt) 2024-02-06
MX2017005749A (es) 2018-01-11
ES2852550T3 (es) 2021-09-13
PH12017500720A1 (en) 2017-10-09
JP2017533218A (ja) 2017-11-09
EP3834837A1 (en) 2021-06-16
EP3215173B1 (en) 2020-01-01
KR20230096142A (ko) 2023-06-29
IL252120A0 (en) 2017-07-31
CO2017005391A2 (es) 2017-10-31
EP3215173A1 (en) 2017-09-13
US20210220433A1 (en) 2021-07-22
US10039804B2 (en) 2018-08-07
PL3215173T3 (pl) 2020-05-18
AU2015341763A1 (en) 2017-06-08
HUE049857T2 (hu) 2020-10-28
CN107073072A (zh) 2017-08-18
US11517609B2 (en) 2022-12-06
TN2017000182A1 (en) 2018-10-19
RS61418B1 (sr) 2021-03-31
IL252120B (en) 2020-07-30
US20200069768A1 (en) 2020-03-05
CA2964524A1 (en) 2016-05-12
US20190160142A1 (en) 2019-05-30
EP3215173B8 (en) 2020-03-11
HRP20210342T1 (hr) 2021-04-30
JP2020183424A (ja) 2020-11-12
DK3215173T3 (da) 2020-03-23
MX387229B (es) 2025-03-04
PL3542812T3 (pl) 2021-07-12

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
HUE053347T2 (hu) Glikopeptid-készítmények
IL254516B (en) Proteins specific for cd137
DK3393510T5 (da) Zikavirusvaccine
IL249313A0 (en) Improved t cell compositions
HUE058288T2 (hu) Pridopidin módosított hatóanyag-leadású készítményei
DK3094351T3 (da) Immunmodulatoriske midler
IL233902B (en) Propulsion system
LT3298027T (lt) Antihelmintiniai depsipeptido junginiai
HUE045024T2 (hu) Poliamid készítmények
EP3340850A4 (en) VACUUM CLEANER
DK3702450T3 (da) Protein
EP3354177A4 (en) VACUUM CLEANER
HUE053624T2 (hu) Ciklosporint tartalmazó készítmények
EP3900838C0 (en) VACUUM INSTALLATION
DK3154689T3 (da) Komplekser
DK3448879T3 (da) Claudin-6 peptider
DE112015006486A5 (de) Inkubationsrinne
HRP20182029T1 (hr) Uti-fuzijski proteini
HUE054584T2 (hu) Maropitant készítmény
DK3099793T3 (da) Protein
DE102015206660A8 (de) Plattenaufteilanlage
DK3154945T3 (da) Komplekser
HUE066069T2 (hu) Mikafungin készítmények
DE112015005898A5 (de) Gurtschlossbringer